- Names New Board of Directors - - FDA Advisory Committee to Review Azfibrocel-T Application for Wrinkles this Week - EXTON, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Isolagen, Inc. has reorganized...
Isolagen, Inc. Receives Delisting Notice from NYSE Amex EXTON, Pa., June 16 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (NYSE Amex: ILE) today announced that on June 15, 2009, the Company and...
EXTON, Pa., May 8 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (NYSE Amex: ILE) today announced that the United States Food and Drug Administration ("FDA") has completed its initial review of...
Isolagen Common Stock to be halted from trading on the NYSE Amex EXTON, Pa., May 6 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (NYSE Amex: ILE) today announced that the Company has entered into...
EXTON, Pa., March 20 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (AMEX: ILE) today announced that on March 17, 2009, it received notice from the Amex (the "Exchange") notifying the Company it...
EXTON, Pa., March 9 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) today announced that the Company has submitted a Biologics License Application (BLA) for Isolagen Therapy(TM), a novel...
-Company Provides Update on Cash Position- EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (AMEX: ILE) announced today positive top-line efficacy results from a Phase II/III...
- Significant Improvements Reported Over Placebo Across All Study Endpoints; Effects of Therapy Observed to Build Over Time - EXTON, Pa., Oct. 22 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc...
EXTON, Pa., Oct. 21 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (AMEX:ILE) announced today that all injections have been completed in the Phase II/III Study IT-A-008 investigating Isolagen...
EXTON, Pa., Oct. 20 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (AMEX:ILE) announced today that the Company will host an investor conference call and webcast on Wednesday, October 22 at 4:30 PM...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.